eli lilly tirzepatide news today recency 3 Lilly's gained FDA approval in December 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly Eli Lilly Experimental Drug Shows

Both tirzepatide and retatrutide have undergone rigorous clinical trials, and the weight loss data from these studies provides the most reliable comparison available

Most notably, at 18 months women on the patch experienced significant improvement in vaginal lubrication, pain during sex, and overall libido and desire

However, some patients do report changes in urination frequency, which is likely due to the bodys adjustment to the medication, hydration, or weight loss

This process occurs when there is an imbalance between free radicals unstable molecules that can damage cellsand antioxidants

Novo Nordisk is not a small company

We understand that dealing with serious health complications related to prescription medications can be overwhelming, stressful, and deeply personal